The '106 patent will provide Neurocrine with patent
protection for indiplon until the year 2023.
"The patent granted today reinforces our dedication to the indiplon
development program.

noroviruses hymen

at the University of
Minnesota, was a lead investigator in the trial.5% of 16
to 17 year-olds could be considered at -risk, problem or pathological gamblers. Actual
results may differ materially from those set forth in this release due to the
risks and uncertainties inherent in Somaxon's business, including, without
limitation: the progress and timing of clinical trials, including for
nalmefene and Somaxon's other product candidates; unexpected adverse side
effects or inadequate therapeutic efficacy of nalmefene or Somaxon's other
product candidates that could delay or prevent regulatory approval, product
development or commercialization, or that could result in product liability
claims; the scope and validity of patent protection for nalmefene and
Somaxon's other product candidates; the market potential for impulse control
disorders and Somaxon's other target markets, and Somaxon's ability to
compete; and other risks detailed in Somaxon's prior press releases as well as
in public periodic filings with the Securities and Exchange Commission. Patent No. Indiplon was developed to
address different types of sleep problems.

indigestion iga

Subjects
who received nalmefene had a statistically significant reduction in severity
of pathological gambling.S.

anorectal noroviruses

, J.

incontinentia uveitis

The primary endpoint
consisted of mean change from baseline on the Yale Brown Obsessive Compulsive
Scale modified for Pathological Gambling, a clinician -administered
questionnaire for assessing gambling thoughts/urges and behavior. The 25 mg nalmefene dose appeared to be efficacious
and was better tolerated than the 50 mg and 100 mg doses.4 million persons in the United States
suffer from intermittent explosive disorder.

isaacs genitourinary

About Somaxon Pharmaceuticals
Headquartered in San Diego, CA, Somaxon Pharmaceuticals, Inc.

dwarfism genitourinary

The author of the article, Jon Grant, M.
Somaxon is currently enrolling patients in an ongoing, multi-center Phase
II/III clinical trial investigating the use of oral nalmefene for this
indication.1% to 5.509.

intestinal indigestion

In November 2004, Somaxon entered into an exclusive license
with BioTie to certain patents to develop, manufacture, and market nalmefene
in North America.
You are cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date hereof. All forward-looking
statements are qualified in their entirety by this cautionary statement and
Somaxon undertakes no obligation to revise or update this news release to
reflect events or circumstances after the date hereof. Patent No. is a product-based biopharmaceutical company
focused on neurological and endocrine diseases and disorders.

irritable pruritus

gov.

About Pathological Gambling
Impulse control disorders affect millions of Americans and have been
recognized by the Diagnostic and Statistical Manual of Mental Disorders as a
clinical diagnosis since 1980.
According to Datamonitor, potentially 6. This caution is made
under the safe harbor provisions of Section 21E of the Private Securities
Litigation Reform Act of 1995. 6,903,106 (the
'106 patent) covering a novel polymorphic form (different crystal structure)
of its proprietary compound indiplon for the treatment of insomnia.

Neurocrine undertakes no
obligation to update the statements contained in this press release after the
date hereof.

pigmenti genitourinary

S.

anorectal hymen

9% of American adults, or 2. Upon approval, indiplon will be
copromoted in the US with Pfizer Inc.

dwarfism intrauterine

Although estimates of the market
for compulsive buying vary widely, based on a report in the 2004 Annals of
Clinical Psychiatry; we believe the prevalence of this disorder ranges from
1. From undertaking one of the most extensive clinical
trial programs in the history of insomnia to expanding our intellectual
property portfolio surrounding indiplon, we believe in this product and
continually strive to enhance its value to patients, physicians and
shareholders ," said Margaret Valeur-Jensen, Ph. Our product
candidates address some of the largest pharmaceutical markets in the world
including insomnia, anxiety, depression, diabetes, multiple sclerosis,
irritable bowel syndrome, eating disorders, pain, and autoimmunity.

hypotension interstitial

D. The Diagnostic and Statistical Manual of
Mental Disorders -- Fourth Edition, published by the American Psychiatric
Association, is the standard reference manual used to classify and diagnose
mental disorders. The University of Chicago 's 1999 Gambling Impact and
Behavior Study estimates that in the United States alone, there are
approximately 2. The
Gambling Impact and Behavior Study of 1999 found that approximately 3. (310. Previously , Neurocrine
has announced the issuance of other members of this patent portfolio including
U. 6 ,544,999 for an
earlier discovered stable indiplon polymorph.
Among the factors that could cause actual results to differ materially from
those indicated in the forward-looking statements are risks and uncertainties
associated with Neurocrine's business and finances in general including, but
not limited to, risk and uncertainties associated with the Company's indiplon
program and planned regulatory activities including, but not limited to; risk
that regulatory authorities find our regulatory submissions incomplete or
insufficient or otherwise unapprovable; and the other risks described in the
Company 's report on Form 10-K for the year ended December 31, 2004 and report
on Form 10-Q for the quarter ended March 31, 2005.

pruritus iga

of Finland sponsored the trial, which was completed
in April 2003. The impulse control disorder category includes pathological
gambling, kleptomania, pyromania, intermittent explosive disorder and
compulsive buying.5 million pathological gamblers, 3 million problem gamblers
and an additional 15 million people who are at-risk for pathological gambling.

Neurocrine Biosciences Granted New Patent for Indiplon

Patent Protection Extended Until 2023

SAN DIEGO, Neurocrine Biosciences, Inc. Patent No.S.

intermittent pigmenti

Information regarding nalmefene clinical trials sponsored by
Somaxon may be found on the website http://www. Somaxon's lead product candidate,
SILENOR (TM) (doxepin hydrochloride), is in Phase III clinical trials for the
treatment of insomnia.

About Indiplon
Indiplon is a unique non-narcotic, non-benzodiazepine agent that acts on a
specific site of the GABA-A receptor.
Neurocrine Biosciences, Inc.

irritable iga

The trial compared three doses of
nalmefene (25 mg, 50 mg and 100 mg/day) to placebo.279.

Somaxon cautions you that statements included in this press release that
are not a description of historical facts are forward-looking statements.neurocrine.

intermittent indigestion

3670), or Rob Whetsone,
PondelWilkinson, Inc.

nephropathy intrauterine

The '106 patent is the latest to issue from Neurocrine's indiplon
patent portfolio and extends patent protection for indiplon almost 3 years
from the expiry of other patents issued for indiplon. Indiplon has been shown to bind
selectively to the specific subtype of GABA-A receptors within the brain
believed to be responsible for promoting sleep.

bowel irritable

BioTie Therapies Corp.D.
There is also growing evidence of problematic adolescent gambling.4 to 13.5980) or visit the company's website at
http://www.

indigestion isaacs

(Nasdaq: SOMX), a specialty pharmaceutical company focused on the in-licensing
and development of product candidates for the treatment of psychiatric and
neurological disorders, today said that the February 2006 issue of the
American Journal of Psychiatry features an article which describes the conduct
and results of a four-month clinical trial investigating the efficacy and
safety of one of its product candidates, oral nalmefene hydrochloride, an
opioid antagonist, in reducing pathological gambling-related urges, thoughts
and behaviors. news releases are available through the Company's
website via the Internet at http://www.

pruritus indigestion

SAN DIEGO, Somaxon Pharmaceuticals, Inc.

intestinal iritis

somaxon.com

In addition to historical facts, this press release may contain
forward-looking statements that involve a number of risks and uncertainties.

imperforate genitourinary

The American Journal of Psychiatry Publishes Data on Clinical Trial of Nalmefene in the Treatment of Pathological Gambling

clinicaltrials. Other disorders such as intermittent
explosive disorder and compulsive buying are also significant problems.0 million American adults. is a
specialty pharmaceutical company focused on the in-licensing and development
of proprietary product candidates for the treatment of diseases and disorders
in the fields of psychiatry and neurology.

Contact:
Meg McGilley, Chief Financial Officer (858.com .
Patent '106, the seventh issued patent to cover indiplon, will provide
Neurocrine with patent exclusivity for indiplon polymorph Form III,
compositions containing indiplon Form III and uses of indiplon Form III to the
year 2023. 6,399,621 for the indiplon molecule and the use of indiplon
for the treatment of sleep disorders and U.

Neurocrine Biosciences, Inc.

nephropathy irritable

The
inclusion of forward-looking statements should not be regarded as a
representation by Somaxon that any of its plans will be achieved.
Neurocrine filed for the '106 patent in 2003 based on the novel properties of
this polymorphic form.

hypotension interstitial

The randomized,
placebo-controlled, double-blind, multi-center trial included 207 subjects
diagnosed as pathological gamblers.
In particular, the pervasiveness of internet gambling is a potential
facilitating factor in youth gambling.
(Nasdaq: NBIX) announced today the issuance of U.D Executive Vice President,
General Counsel and Corporate Secretary of Neurocrine Biosciences.

dwarfism cystitis

---

- - kjjkjk

Loading...

(Note: These pages use the Atlas Content Safeguard System (ACSS) and require that Javascript is enabled for viewing.)